Fas ligand-avidin/streptavidin fusion proteins

Details Fas ligand-avidin/streptavidin fusion proteins Fas ligand-avidin/streptavidin fusion proteins

2011-04-19

2011-04-19

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S195110, C530S350000, C514S002600

Reexamination Certificate

active

07927602

ABSTRACT:
This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.

REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6042826 (2000-03-01), Caligiuri et al.
patent: 6046310 (2000-04-01), Queen et al.
patent: 6060054 (2000-05-01), Staerz
patent: 2003/0095977 (2003-05-01), Goshorn et al.
patent: WO-97/18307 (1997-05-01), None
patent: WO 97/33617 (1997-09-01), None
patent: WO-99/17801 (1999-04-01), None
patent: WO-01/52664 (2001-07-01), None
Dubel, S, et al. 1995. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Methods. vol. 178, p. 201-209.
Daniels, G.M. and Amara, S.G. 1998. Selective labeling of neurotransmitter transporters at the cell surface. Methods in Enzymology. vol. 296, p. 307-318.
Pahler, A, et al. 1987. Characterization and crystallization of core streptavidin. J. Biological Chemistry. vol. 262(29), p. 13933-13937.
Nagata S, et al. Fas and fas ligand: Ipr and gld mutations. 1995. Immunology Today, vol. 16(1), pp. 39-43).
Hofmann K. et al. Iminobiotin affinity columns and their application to retrieval of streptavidin. Proc. Natl. Acad. Sci. USA. 1980. vol. 77, pp. 4666-4668.
Ashkenasy N, et al. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation, 2003, vol. 107, p. 1-7.
Pearl-Yafe M, et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells, 2007, vol. 25, p. 1448-1455.
Yolcu E.S. et al. Induction of tolerance to cardiac allografts using doner splenocytes engineered to display on their surfaces an exogenous fas ligand protein. Journal of Immunology, 2008, vol. 181, p. 931-939.
Yolcu, E.S. et al. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity, 2002, vol. 17, p. 795-808.
Shirwan, H. Bone marrow cells engineered with SA-FasL protein establish durable multilineage mixed allogenic chimerism. Unpublished results, discussed in the interview of Apr. 12, 2010.
Yolcu, E.S. Engineering pancreatic islets with a novel form of FasL protein as a robust means of achieving transplantation tolerance. Unpublished results, discussed in the interview of Apr. 12, 2010.
Chen, A.,et al. ,“Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fustion Protein Transfer Method”,The Journal of Immunology, 164, (2000),705-711.
Darling, D.,et al. ,“In Vitro Immune Modulation by Antibodies Coupled to Tumour Cells”,Gene Therapy, 4, (1997),1350-1360.
Sano, Takeshi.,et al. ,“A streptavidin-metallothionein chimera that allows specific labeling of biological materials with many different heavy metal ions”,Proc. Nat'l. Acad. Sci., vol. 89, (Mar. 1992),1534-1538.
Airenne et al., “Rapid purification of recombinant proteins fused to chicken avidin” Gene 167: 63-68 (1995).

Affiliated with

Also associated with

Rating

Fas ligand-avidin/streptavidin fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fas ligand-avidin/streptavidin fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fas ligand-avidin/streptavidin fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2738711